These consistent differences suggest that there is a specific biological response in T-ALL samples with NOTCH1 mutations and loss of CDKN2A that potentially involves enhanced NOTCH3 expression. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.